Critical Outcome Tec (COTQF) 0.1782 $COTQF
Critical Outcome Technologies Planning Phase 1 Clinical Trial of COTI-2 in Recurrent Head and Neck Cancers
Marketwired - Tue Jan 20, 8:05AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT) (OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it has executed a material transfer agreement ("MTA" with Dr. John Yoo, MD, FRCSC, FACS, and his team at the London Health Sciences Centre's London Regional Cancer Program and Western University, for the continued evaluation of COTI-2 for the treatment of patients with recurrent head and neck squamous cell cancer ("HNSCC" .
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Closes Financing
Marketwired - Mon Dec 22, 8:21AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Corporation" the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced the closing of a non-brokered private placement of 970,000 units (the "Units" at a price of CAD $0.255 per Unit for gross proceeds of $247,350.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Inc. Extends Warrants Set to Expire December 20, 2014
Marketwired - Thu Dec 18, 4:39PM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it is amending the expiry date of 2,003,498 common share purchase warrants ("Warrants" issued as part of a non-brokered private placement on June 21, 2013, that were scheduled to expire on December 20, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue. These Warrants represented the second tranche of the Company's spring 2013 private placement.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Reports Fiscal 2015 Second Quarter Results
Marketwired - Wed Dec 17, 5:05PM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company" the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, reported its financial and operating results today for the three and six month periods ended October 31, 2014.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Completes Private Placement
Marketwired - Wed Nov 26, 7:32AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company" the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, completed the third tranche of its previously announced non-brokered private placement with the issuance of 3,054,000 units (the "Units" at a price of USD $0.23 per Unit for gross Canadian dollar proceeds of approximately $793,000. In aggregate, the Company raised gross Canadian proceeds from the offering of approximately $2,629,000 through the sale of 10,177,760 Units.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwired - Wed Nov 19, 3:20PM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it is amending the expiry date of 2,412,397 common share purchase warrants ("Warrants" issued as part of a non-brokered private placement on May 31, 2013, that were scheduled to expire on November 30, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Closes Second Tranche of Financing
Marketwired - Fri Nov 07, 7:54AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company" the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, completed a second tranche of its previously announced non-brokered private placement with the issuance of 5,111,062 units (the "Units" at a price of USD $0.23 per Unit for gross Canadian dollar proceeds of approximately $1,319,000. In aggregate, the Corporation has raised gross Canadian proceeds from the offering of approximately $1,836,000 through the sale of 7,123,760 Units.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Reports Successful Completion of Two-Species Toxicity Testing for COTI-2
Marketwired - Thu Oct 30, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that its lead oncology drug candidate, COTI-2, successfully completed two-species repeated dose toxicity studies in anticipation of a United States Food and Drug Administration ("FDA" Investigational New Drug ("IND" filing.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Awards Stock Options
Marketwired - Thu Oct 23, 9:38PM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it awarded 1,801,099 stock options to directors, officers, and employees under the Company's Stock Option Plan on October 22, 2014. The options awarded to directors were made as a retainer for their service on the Board and its committees for the ensuing year. The options were awarded to officers and employees by the Board on a discretionary basis for their meritorious efforts during the past year. The options have a five year life with 25% vesting occurring at the end of each quarter from the date of grant as applicable. The exercise price is $0.29 and represents the closing price of the Company's common shares on October 21, 2014, the last trading day reported on the TSX Venture Exchange prior to the grant meeting date.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Provides Summary of Recent Achievements and Future Milestones at Annual General Meeting
Marketwire Canada - Thu Oct 23, 8:57AM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT)(OTCQB:COTQF), the biopharmaceutical company using machine learning to rapidly develop targeted therapies, announced today that its President & Chief Executive Officer, Dr. Wayne Danter, provided a summary of the key business achievements during the past year and an overview of plans moving forward at the Company's Annual General and Special Meeting (AGM) of Shareholders held on Tuesday, October 21, 2014.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Planning Phase 1 Clinical Trial of COTI-2 in Recurrent Head and Neck Cancers
Marketwired - Tue Jan 20, 8:05AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT) (OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it has executed a material transfer agreement ("MTA" with Dr. John Yoo, MD, FRCSC, FACS, and his team at the London Health Sciences Centre's London Regional Cancer Program and Western University, for the continued evaluation of COTI-2 for the treatment of patients with recurrent head and neck squamous cell cancer ("HNSCC" . COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Closes Financing
Marketwired - Mon Dec 22, 8:21AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Corporation"
the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced the closing of a non-brokered private placement of 970,000 units (the "Units" at a price of CAD $0.255 per Unit for gross proceeds of $247,350. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Inc. Extends Warrants Set to Expire December 20, 2014
Marketwired - Thu Dec 18, 4:39PM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it is amending the expiry date of 2,003,498 common share purchase warrants ("Warrants" issued as part of a non-brokered private placement on June 21, 2013, that were scheduled to expire on December 20, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue. These Warrants represented the second tranche of the Company's spring 2013 private placement. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Reports Fiscal 2015 Second Quarter Results
Marketwired - Wed Dec 17, 5:05PM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"
the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, reported its financial and operating results today for the three and six month periods ended October 31, 2014. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Completes Private Placement
Marketwired - Wed Nov 26, 7:32AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"
the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, completed the third tranche of its previously announced non-brokered private placement with the issuance of 3,054,000 units (the "Units" at a price of USD $0.23 per Unit for gross Canadian dollar proceeds of approximately $793,000. In aggregate, the Company raised gross Canadian proceeds from the offering of approximately $2,629,000 through the sale of 10,177,760 Units. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwired - Wed Nov 19, 3:20PM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it is amending the expiry date of 2,412,397 common share purchase warrants ("Warrants"
issued as part of a non-brokered private placement on May 31, 2013, that were scheduled to expire on November 30, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Closes Second Tranche of Financing
Marketwired - Fri Nov 07, 7:54AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"
the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, completed a second tranche of its previously announced non-brokered private placement with the issuance of 5,111,062 units (the "Units" at a price of USD $0.23 per Unit for gross Canadian dollar proceeds of approximately $1,319,000. In aggregate, the Corporation has raised gross Canadian proceeds from the offering of approximately $1,836,000 through the sale of 7,123,760 Units. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Reports Successful Completion of Two-Species Toxicity Testing for COTI-2
Marketwired - Thu Oct 30, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that its lead oncology drug candidate, COTI-2, successfully completed two-species repeated dose toxicity studies in anticipation of a United States Food and Drug Administration ("FDA" Investigational New Drug ("IND" filing. COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Awards Stock Options
Marketwired - Thu Oct 23, 9:38PM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF), the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it awarded 1,801,099 stock options to directors, officers, and employees under the Company's Stock Option Plan on October 22, 2014. The options awarded to directors were made as a retainer for their service on the Board and its committees for the ensuing year. The options were awarded to officers and employees by the Board on a discretionary basis for their meritorious efforts during the past year. The options have a five year life with 25% vesting occurring at the end of each quarter from the date of grant as applicable. The exercise price is $0.29 and represents the closing price of the Company's common shares on October 21, 2014, the last trading day reported on the TSX Venture Exchange prior to the grant meeting date.
COT.VN: 0.230 (+0.005)
Critical Outcome Technologies Provides Summary of Recent Achievements and Future Milestones at Annual General Meeting
Marketwire Canada - Thu Oct 23, 8:57AM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT)(OTCQB:COTQF), the biopharmaceutical company using machine learning to rapidly develop targeted therapies, announced today that its President & Chief Executive Officer, Dr. Wayne Danter, provided a summary of the key business achievements during the past year and an overview of plans moving forward at the Company's Annual General and Special Meeting (AGM) of Shareholders held on Tuesday, October 21, 2014.
COT.VN: 0.230 (+0.005)
